Payment overview · 2025
General Payments
$659.78
25 reported records · 7 companies
Healthcare provider profile · identity verified
Omar J Bashir, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · BEAUMONT, CA · NPI 1891730479
Verified facts
What the public records show
CMS Open Payments records show Omar J Bashir, D.O. received $659.78 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 518 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 380 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $186.59 | 28.3% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $178.81 | 27.1% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $121.91 | 18.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $92.91 | 14.1% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.10 | 6.1% | 2 | 2025 |
| Eko Health, Inc. | Unresolved — no canonical attribution shown | $20.00 | 3.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.46 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $639.78 | 24 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $186.59 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $167.93 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $121.91 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $92.91 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $57.10 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.10 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.81 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $10.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 380 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 518 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 239 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
87 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
518 | 90 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
17 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
78 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
239 | 53 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
380 | 72 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 924 | 296 |
| Amlodipine Besylate | Amlodipine Besylate | 656 | 195 |
| Losartan Potassium | Losartan Potassium | 558 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 548 | 150 |
| Lisinopril | Lisinopril | 536 | 168 |
| Tamsulosin Hcl | Tamsulosin Hcl | 526 | 137 |
| Jardiance | Empagliflozin | 518 | 90 |
| Omeprazole | Omeprazole | 513 | 138 |
| Gabapentin | Gabapentin | 496 | 118 |
| Metformin Hcl | Metformin Hcl | 479 | 125 |
| Potassium Chloride | Potassium Chloride | 428 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 403 | 107 |
| Furosemide | Furosemide | 394 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 393 | 120 |
| Eliquis | Apixaban | 380 | 72 |
| Alendronate Sodium | Alendronate Sodium | 375 | 96 |
| Escitalopram Oxalate | Escitalopram Oxalate | 364 | 91 |
| Trazodone Hcl | Trazodone Hcl | 326 | 89 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 299 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 283 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 80 |
| Carvedilol | Carvedilol | 249 | 61 |
| Pravastatin Sodium | Pravastatin Sodium | 241 | 68 |
| Ozempic | Semaglutide | 239 | 53 |
| Glipizide | Glipizide | 223 | 61 |
| Finasteride | Finasteride | 214 | 54 |
| Spironolactone | Spironolactone | 211 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 197 | 72 |
| Donepezil Hcl | Donepezil Hcl | 187 | 46 |
| Simvastatin | Simvastatin | 178 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 169 | 38 |
| Allopurinol | Allopurinol | 168 | 45 |
| Meloxicam | Meloxicam | 160 | 43 |
| Famotidine | Famotidine | 156 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 155 | 53 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 148 | 34 |
| Celecoxib | Celecoxib | 142 | 29 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 140 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 136 | 29 |
| Valsartan | Valsartan | 124 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 30 |
| Pregabalin | Pregabalin | 119 | 22 |
| Azelastine Hcl | Azelastine Hcl | 115 | 48 |
| Benazepril Hcl | Benazepril Hcl | 115 | 27 |
| Tramadol Hcl | Tramadol Hcl | 114 | 45 |
| Ketoconazole | Ketoconazole | 109 | 57 |
| Synthroid | Levothyroxine Sodium | 108 | 34 |
| Montelukast Sodium | Montelukast Sodium | 105 | 33 |
| Alprazolam | Alprazolam | 104 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 103 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 102 | 58 |
| Sildenafil Citrate | Sildenafil Citrate | 99 | 22 |
| Folic Acid | Folic Acid | 92 | 22 |
| Cephalexin | Cephalexin | 91 | 74 |
| Cefdinir | Cefdinir | 89 | 71 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 37 |
| Farxiga | Dapagliflozin Propanediol | 87 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 86 | 17 |
| Atenolol | Atenolol | 85 | 26 |
| Memantine Hcl | Memantine Hcl | 85 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 83 | 20 |
| Spiriva Respimat | Tiotropium Bromide | 83 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 16 |
| Estradiol | Estradiol | 76 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 22 |
| Solifenacin Succinate | Solifenacin Succinate | 73 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 72 | 19 |
| Lactulose | Lactulose | 69 | 32 |
| Prednisone | Prednisone | 69 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 18 |
| Metformin Hcl Er | Metformin Hcl | 68 | 24 |
| Sotalol | Sotalol Hcl | 67 | 16 |
| Valacyclovir | Valacyclovir Hcl | 67 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 19 |
| Myrbetriq | Mirabegron | 65 | 19 |
| Irbesartan | Irbesartan | 64 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 64 | 17 |
| Ibuprofen | Ibuprofen | 62 | 25 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 60 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 50 |
| Meclizine Hcl | Meclizine Hcl | 59 | 25 |
| Warfarin Sodium | Warfarin Sodium | 59 | 14 |
| Ezetimibe | Ezetimibe | 58 | 18 |
| Propranolol Hcl | Propranolol Hcl | 56 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 16 |
| Sertraline Hcl | Sertraline Hcl | 54 | 15 |
| Januvia | Sitagliptin Phosphate | 53 | 16 |
| Lovastatin | Lovastatin | 52 | 15 |
| Azithromycin | Azithromycin | 51 | 40 |
| Primidone | Primidone | 51 | 13 |
| Mirtazapine | Mirtazapine | 50 | 21 |
| Testosterone | Testosterone | 50 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 49 | 14 |
| Xarelto | Rivaroxaban | 49 | 13 |
| Lamotrigine | Lamotrigine | 48 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 38 |
| Terazosin Hcl | Terazosin Hcl | 45 | 13 |
| Belsomra | Suvorexant | 44 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 44 | 17 |
| Ondansetron Odt | Ondansetron | 44 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 14 |
| Ramipril | Ramipril | 43 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 42 | suppressed |
| Rybelsus | Semaglutide | 42 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 35 |
| Creon | Lipase/Protease/Amylase | 41 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Fluocinonide | Fluocinonide | 39 | 23 |
| Levetiracetam | Levetiracetam | 38 | 12 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | 11 |
| Eszopiclone | Eszopiclone | 37 | suppressed |
| Methocarbamol | Methocarbamol | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | 11 |
| Procto-Med Hc | Hydrocortisone | 37 | 15 |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 28 |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 25 |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | 15 |
| Calcium Acetate | Calcium Acetate | 32 | 13 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 30 | 16 |
| Latanoprost | Latanoprost | 30 | 11 |
| Lorazepam | Lorazepam | 30 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 29 | suppressed |
| Febuxostat | Febuxostat | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 28 | 25 |
| Constulose | Lactulose | 27 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 15 |
| Zenpep | Lipase/Protease/Amylase | 27 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | 12 |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 24 | 17 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | 13 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Ciclopirox | Ciclopirox | 19 | 11 |
| Dutasteride | Dutasteride | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Cefixime | Cefixime | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Victoza 2-Pak | Liraglutide | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Egrifta Sv | Tesamorelin Acetate | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $659.78 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, ELIQUIS, JARDIANCE, LEQVIO, NURTEC ODT, Ozempic, Wegovy, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error